BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

6:11 PM
 | 
Jun 01, 2010
 |  BC Extra  |  Company News

FDA approves Cysview

FDA approved an NDA from Photocure ASA (OSE:PHO) for Cysview hexaminolevulinate to detect non-muscle-invasive papillary cancer of the bladder in patients with known or suspected bladder cancer....

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >